Global and India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Market Report & Forecast 2024-2034
The global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during the review period (2024-2034).
In India, the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period 2024-2034.
The global key players of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors include Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation and Jacobio Pharmaceuticals, etc. The global five biggest players hold a share of % in 2022.
This report focuses on global and India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors will continue to grow rapidly in the future.
Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Scope and Market Size
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.
For India market, this report focuses on the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
Amgen
Mirati Therapeutics
Novartis
Genentech
Verastem Oncology
Revolution Medicines
Cardiff Oncology
Immuneering Corporation
Jacobio Pharmaceuticals
BridgeBio Pharma
Deciphera Pharmaceuticals
Elicio Therapeutics
InventisBio
Gritstone Bio
D3 Bio
Segment by Type
Direct Inhibitors
Signal transduction inhibitors
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
In India, the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period 2024-2034.
The global key players of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors include Amgen, Mirati Therapeutics, Novartis, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation and Jacobio Pharmaceuticals, etc. The global five biggest players hold a share of % in 2022.
This report focuses on global and India Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2024, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors will continue to grow rapidly in the future.
Global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors Scope and Market Size
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.
For India market, this report focuses on the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.
By Company
Amgen
Mirati Therapeutics
Novartis
Genentech
Verastem Oncology
Revolution Medicines
Cardiff Oncology
Immuneering Corporation
Jacobio Pharmaceuticals
BridgeBio Pharma
Deciphera Pharmaceuticals
Elicio Therapeutics
InventisBio
Gritstone Bio
D3 Bio
Segment by Type
Direct Inhibitors
Signal transduction inhibitors
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors definition, global market size, India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Inhibitors revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices